Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
FAQ
- What is Pacira BioSciences, Inc.'s D&A?
- Pacira BioSciences, Inc. (PCRX) reported D&A of $21.33M in Q1 2026.
- How has Pacira BioSciences, Inc.'s D&A changed year-over-year?
- Pacira BioSciences, Inc.'s D&A increased by 0.8% year-over-year, from $21.17M to $21.33M.
- What is the long-term trend for Pacira BioSciences, Inc.'s D&A?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s D&A has grown at a 33.6% compound annual growth rate (CAGR), from $28.55M to $91.02M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Pacira BioSciences, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude